Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.
Passeron T, Ezzedine K, Hamzavi I, van Geel N, Schlosser BJ, Wu X, Huang X, Soliman AM, Rosmarin D, Harris JE, Camp HS, Pandya AG. Passeron T, et al. Among authors: camp hs. EClinicalMedicine. 2024 May 31;73:102655. doi: 10.1016/j.eclinm.2024.102655. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 38873632 Free PMC article.
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial.
Brunner HI, Shmagel A, Horneff G, Foeldvari I, Antón J, Ramanan AV, Qian Y, Unnebrink K, Hao S, Camp HS, Khan N, Liu W, Mohamed MF. Brunner HI, et al. Among authors: camp hs. Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25465. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39542836
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A. Fleischmann R, et al. Among authors: camp hs. RMD Open. 2024 Jul 25;10(3):e003918. doi: 10.1136/rmdopen-2023-003918. RMD Open. 2024. PMID: 39059811 Free PMC article. Clinical Trial.
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
van Vollenhoven R, Strand V, Takeuchi T, Chávez N, Walter PM, Singhal A, Swierkot J, Khan N, Bu X, Li Y, Penn SK, Camp HS, Aelion J. van Vollenhoven R, et al. Among authors: camp hs. Arthritis Res Ther. 2024 Jul 29;26(1):143. doi: 10.1186/s13075-024-03358-x. Arthritis Res Ther. 2024. PMID: 39075620 Free PMC article. Clinical Trial.
55 results